PLCG2 and neoplasm: Identification of the relevant molecular mechanism is likely to facilitate the development of inhibitors specifically targeting S707 mutant, but not wild-type PLCγ2, in patients suffering from acquired tumor drug resistance or hereditary autoinflammation [30, 31].